(First Edition)
The field of cell and gene therapy is transforming medicine, offering innovative treatments that address diseases once thought untreatable. For pharma professionals and investors accustomed to small molecules and traditional biologics, navigating this new landscape can be challenging. However, with the right knowledge and resources, transitioning into cell and gene therapy becomes easier.
The Expanding World of Cell and Gene Therapy
According to GlobalData’s estimates, the global CGT market is projected to reach sales of $80bn
by 2029. This growth is due to significant scientific advancements, regulatory approvals for innovative treatments, and rising investments from industry giants and biotech startups. This rapidly growing field, encompassing new therapeutics, biotech tools, equipment, and specialized services, is reshaping healthcare and investment opportunities. The implications are profound, promising not just treatments, but potential cures for genetic and rare diseases.
New Therapeutics and Technologies
Therapeutics: Groundbreaking therapies like CAR-T (chimeric antigen receptor T-cell) treatments and CRISPR gene editing are at the forefront.
Biotech Tools and Equipment: The development of these therapies requires sophisticated tools and equipment for manufacturing and scaling up production. Automation, microfluidics and miniaturization will play an important role in the next generation equipment used develop, manufacturing and deliver these products.
Specialized Services: The complexity of developing these therapies has led to the growth of specialized contract research and manufacturing organizations (CROs and CDMOs). Many CROs and CDMOs have been set up in the past 5-8 years to tackle the challenges of these innovative medicinal products.
Opportunities for Investors and Executives
Venture capitalists have been quick to recognize the promise of cell and gene therapy, investing over $4 billion in recent years. For executives and investors looking to better understand this space, our “Cell and Gene Therapy Quick Guide for Executives and Investors” offers valuable insights into this dynamic space.
Ready to discuss your next cell and gene therapy project?
If you have questions or would like further guidance, don’t hesitate to email Fabio. We’re here to help you understand this dynamic and evolving landscape.
Other useful resources:
Global Cell and Gene Therapy Companies (Database)
FDA Cell and Gene Therapy Guidances